Author:
Sarak Taner,Saricam Ersin,Taner Abbas
Publisher
Journal of Health Sciences and Medicine
Reference20 articles.
1. 1-Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 Eur Heart J. 2015 14; 36(47):3320-31.
2. 2-Herbert JM, Savi P. P2Y12, a new paltelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003;3:113-22
3. 3-Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5
4. 4-Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.J Am Coll Cardiol. 2016 Mar 15; 67(10):1235-50.
5. 5-Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, at al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. Eur Heart J. 2016 Jan 14; 37(3):267-315.